Decipher® is a genomic test that helps predict the aggressiveness of prostate cancer and guides treatment decisions after biopsy or surgery.
Risk Stratification: Distinguishes between low and high risk of metastasis or progression
Personalized Care: Informs choice between active surveillance, radiation, or hormone therapy
Post-Surgery Clarity: Predicts likelihood of recurrence after prostatectomy
Clinically Validated: Backed by over 70 peer-reviewed studies and included in NCCN guidelines
Non-Invasive: Requires only a sample of tumor tissue (biopsy or surgical specimen)
Decipher® analyzes the activity of 22 genes involved in cancer progression to produce a genomic risk score (low, intermediate, high).
This score helps physicians and patients make more informed decisions about the need for further treatment or the appropriateness of observation.
A tumor sample is submitted to the lab (from biopsy or prostatectomy)
22 genes linked to cancer aggressiveness are analyzed
genomic classifier report is created
Results are reviewed with the patient to guide care planning
Men recently diagnosed with localized prostate cancer considering treatment options
Patients with adverse pathology after prostatectomy
Individuals with rising PSA after surgery to assess risk of recurrence
Men choosing between active surveillance and more aggressive interventions
